Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Eshwaran Narayanan & Rajesh Wakaskar. (2018) Utilization of nanoparticulate therapy in cancer targeting. Cogent Medicine 5:1.
Read now
Read now
Yuanyuan Wang, Xin Qi, Dehai Li, Tianjiao Zhu, Xiaomei Mo & Jing Li. (2014) Anticancer efficacy and absorption, distribution, metabolism, and toxicity studies of Aspergiolide A in early drug development. Drug Design, Development and Therapy 8, pages 1965-1977.
Read now
Read now
Yongming Zhang, Aidong Li, Zheng Wang, Zhikai Han, Jie He & Jie Ma. (2008) Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model. Journal of Drug Targeting 16:9, pages 679-687.
Read now
Read now
Atiar M Rahman, Syed Wamique Yusuf & Michael S Ewer. (2007) Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. International Journal of Nanomedicine 2:4, pages 567-583.
Read now
Read now
Alberto A. Gabizon, Hilary Shmeeda & Samuel Zalipsky. (2006) Pros and Cons of the Liposome Platform in Cancer Drug Targeting. Journal of Liposome Research 16:3, pages 175-183.
Read now
Read now
Alberto A. Gabizon. (2001) Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. Cancer Investigation 19:4, pages 424-436.
Read now
Read now
. (2000) Literature Alerts. Journal of Microencapsulation 17:4, pages 519-534.
Read now
Read now
Articles from other publishers (25)
Iftikhar Khan, Katie Lau, Ruba Bnyan, Chahinez Houacine, Matthew Roberts, Abdullah Isreb, Abdelbary Elhissi & Sakib Yousaf. (2020) A Facile and Novel Approach to Manufacture Paclitaxel-Loaded Proliposome Tablet Formulations of Micro or Nano Vesicles for Nebulization. Pharmaceutical Research 37:6.
Crossref
Crossref
M. Studenovsky, L. Sivak, O. Sedlacek, R. Konefal, V. Horkova, T. Etrych, M. Kovar, B. Rihova & M. Sirova. (2018) Polymer nitric oxide donors potentiate the treatment of experimental solid tumours by increasing drug accumulation in the tumour tissue. Journal of Controlled Release 269, pages 214-224.
Crossref
Crossref
András Füredi, Kornélia Szebényi, Szilárd Tóth, Mihály Cserepes, Lilla Hámori, Veronika Nagy, Edina Karai, Péter Vajdovich, Tímea Imre, Pál Szabó, Dávid Szüts, József Tóvári & Gergely Szakács. (2017) Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. Journal of Controlled Release 261, pages 287-296.
Crossref
Crossref
Saina Yang, Feiyan Zhu, Qian Wang, Fuxin Liang, Xiaozhong Qu, Zhihua Gan & Zhenzhong Yang. (2016)
Nano-rods of doxorubicin with poly(
l
-glutamic acid) as a carrier-free formulation for intratumoral cancer treatment
. Journal of Materials Chemistry B 4:45, pages 7283-7292.
Crossref
Crossref
Darren Lars Stirland, Joseph W. Nichols, Seiji Miura & You Han Bae. (2013) Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice. Journal of Controlled Release 172:3, pages 1045-1064.
Crossref
Crossref
Emily M. Curtis & Carol K. Hall. (2013) Molecular Dynamics Simulations of DPPC Bilayers Using “LIME”, a New Coarse-Grained Model. The Journal of Physical Chemistry B 117:17, pages 5019-5030.
Crossref
Crossref
BS Hendriks, JG Reynolds, SG Klinz, E Geretti, H Lee, SC Leonard, DF Gaddy, CW Espelin, UB Nielsen & TJ Wickham. (2012) Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug‐Specific Parameters in Local Delivery to Tumors. CPT: Pharmacometrics & Systems Pharmacology 1:11, pages 1-11.
Crossref
Crossref
I. Craig Henderson. 2011. Drug Delivery in Oncology. Drug Delivery in Oncology
907
949
.
Joy M. Fulbright, Winston Huh, Pete Anderson & Joya Chandra. (2010) Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?. Current Oncology Reports 12:6, pages 411-419.
Crossref
Crossref
Tal Grenader & Alberto Gabizon. (2010) What Is the Right Way to Administer Pegylated Liposomal Doxorubicin in Breast Cancer Therapy?. Journal of Clinical Oncology 28:12, pages e193-e194.
Crossref
Crossref
Han-Chung Wu & De-Kuan Chang. (2010) Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy. Journal of Oncology 2010, pages 1-8.
Crossref
Crossref
David Vetvicka, Martin Hruby, Ondrej Hovorka, Tomas Etrych, Miroslav Vetrik, Lubomir Kovar, Marek Kovar, Karel Ulbrich & Blanka Rihova. (2009) Biological Evaluation of Polymeric Micelles with Covalently Bound Doxorubicin. Bioconjugate Chemistry 20:11, pages 2090-2097.
Crossref
Crossref
Emily Gullotti & Yoon Yeo. (2009) Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery. Molecular Pharmaceutics 6:4, pages 1041-1051.
Crossref
Crossref
De-Kuan Chang, Chien-Yu Chiu, Szu-Yao Kuo, Wei-Chuan Lin, Albert Lo, Yi-Ping Wang, Pi-Chun Li & Han-Chung Wu. (2009) Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors. Journal of Biological Chemistry 284:19, pages 12905-12916.
Crossref
Crossref
De-Kuan Chang, Chin-Tarng Lin, Chien-Hsun Wu & Han-Chung Wu. (2009) A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer. PLoS ONE 4:1, pages e4171.
Crossref
Crossref
Alberto Gabizon, Rut Isacson, Ora Rosengarten, Dina Tzemach, Hilary Shmeeda & Rama Sapir. (2007) An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemotherapy and Pharmacology 61:4, pages 695-702.
Crossref
Crossref
Tong-Young Lee, Chin-Tarng Lin, Szu-Yao Kuo, De-Kuan Chang & Han-Chung Wu. (2007) Peptide-Mediated Targeting to Tumor Blood Vessels of Lung Cancer for Drug Delivery. Cancer Research 67:22, pages 10958-10965.
Crossref
Crossref
Alberto Gabizon. 2006. Nanotechnology for Cancer Therapy. Nanotechnology for Cancer Therapy
595
611
.
Haifeng Song, Jin Zhang, Zhikai Han, Xueyan Zhang, Zheng Li, Lisheng Zhang, Ming Fu, Chen Lin & Jie Ma. (2005) Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer Chemotherapy and Pharmacology 57:5, pages 591-598.
Crossref
Crossref
Craig Henderson. 2006. Textbook of Breast Cancer. Textbook of Breast Cancer
257
287
.
Marek Langner & Arkadiusz Kozubek. 2006. Nanocarrier Technologies. Nanocarrier Technologies
113
138
.
I. Craig Henderson. (2004) Introduction. Seminars in Oncology 31, pages 1-4.
Crossref
Crossref
David M. Vail, Michael A. Amantea, Gail T. Colbern, Francis J. Martin, Ralf A. Hilger & Peter K. Working. (2004) Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Seminars in Oncology 31, pages 16-35.
Crossref
Crossref
Luigi Cattel, Maurizio Ceruti & Franco Dosio. (2018) From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy. Tumori Journal 89:3, pages 237-249.
Crossref
Crossref
Alberto Gabizon, Hilary Shmeeda & Yechezkel Barenholz. (2003) Pharmacokinetics of Pegylated Liposomal Doxorubicin. Clinical Pharmacokinetics 42:5, pages 419-436.
Crossref
Crossref